DCM
PCVX icon

Driehaus Capital Management’s Vaxcyte PCVX Stock Holding History

Driehaus Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73,376
Closed -$2.39M – 493
2025
Q2 		$2.39M Sell
73,376
-987,487
-93% -$32.4M 0.02% 325
2025
Q1 		$40.1M Sell
1,060,863
-105,970
-9% -$8.47M 0.39% 78
2024
Q4 		$95.5M Sell
1,166,833
-554,463
-32% -$55.1M 0.79% 24
2024
Q3 		$197M Sell
1,721,296
-213,451
-11% -$19.2M 1.69% 5
2024
Q2 		$146M Buy
1,934,747
+66,940
+4% +$4.56M 1.41% 9
2024
Q1 		$128M Buy
1,867,807
+193,439
+12% +$13.4M 1.27% 12
2023
Q4 		$105M Buy
1,674,368
+350,484
+26% +$18.2M 1.27% 9
2023
Q3 		$67.5M Buy
1,323,884
+134,027
+11% +$6.61M 0.88% 22
2023
Q2 		$59.4M Buy
1,189,857
+575,951
+94% +$27.3M 0.75% 26
2023
Q1 		$23M Sell
613,906
-216,889
-26% -$9.2M 0.32% 99
2022
Q4 		$39.8M Buy
830,795
+247,189
+42% +$9.7M 0.59% 42
2022
Q3 		$14M Buy
583,606
+35,416
+6% +$898K 0.21% 146
2022
Q2 		$11.9M Buy
548,190
+458,190
+509% +$10.6M 0.19% 173
2022
Q1 		$2.17M Buy
+90,000
New +$1.97M 0.03% 318

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Driehaus Capital Management's PCVX Position: Q3 2025 in Review

Driehaus Capital Management sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 73,376 shares — an estimated $2.39M sold.

Driehaus Capital Management first reported a position in PCVX in Q1 2022 and held it in 14 quarters. The position peaked at $197M in Q3 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Driehaus Capital Management reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 73,376 Vaxcyte shares in Q3 2025, an estimated $2.39M.
  • Driehaus Capital Management first reported a position in Vaxcyte in Q1 2022 and held it in 14 quarters.
  • Driehaus Capital Management's Vaxcyte position peaked at $197M in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Driehaus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.